New Delhi: The Drugs Controller General of India (DCGI) has , after cautious examination, accorded permission to conduct the Phase 2/3 scientific trial of Bharat Biotech’s Covaxin within the age group 2 to 18 years.
This comes as a reassuring replace whereas consultants predict that the third wave of Coronavirus pandemic in India may most severely have an effect on youngsters.
ALSO READ | PM Narendra Modi To Hold Key Meeting With 54 DMs Of 10 States On May 20 To Review COVID Situation
“The National Regulator of the country, the Drugs Controller General of India (DCGI), after careful examination, has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trial of Covaxin (COVID vaccine) in the age group 2 to 18 years, to its manufacturer Bharat Biotech Ltd on 12.05.2021,” the official assertion learn.
It additional knowledgeable that Hyderabad-based Bharat Biotech Ltd had proposed to hold out a Phase- 2/3 scientific trial of Covaxin within the age group of 2 to 18 years. The trial can be carried out on 525 wholesome volunteers.
The vaccine can be given by intramuscular route in two doses on day 0 and day 28, within the trial.
As a fast regulatory response, the proposal was deliberated within the Subject Expert Committee (SEC) (COVID-19) on 11.05.2021. The Committee after detailed deliberation beneficial for grant of permission to conduct the proposed Phase II/III scientific trial to sure situations.
This transfer is available in as India recorded 3,62,727 new COVID-19 instances, 3,52,181 discharges, and 4,120 deaths within the final 24 hours, as knowledgeable by Union Health Ministry.
The contemporary surge has taken the overall caseload to 2,37,03,665, whereas whole discharges are at 1,97,34,823 and the general demise toll has reached 2,58,317. Active instances are reported to be 37,10,525.
Check out under Health Tools-
Calculate Your Body Mass Index ( BMI )
(*2*)Source hyperlink
